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Abstract  
Introduction 
The bile salt export pump (BSEP/ABCB11), residing in the apical membrane of 
hepatocyte, mediates the secretion of bile salts into the bile. A range of human diseases is 
associated with the malfunction of BSEP, including fatal hereditary liver disorders and mild 
cholestatic conditions. Manifestation of these diseases primarily depends on the mutation 
type; however, other factors such as hormonal changes and drug interactions can also trigger 
or influence the related diseases. 
Areas covered 
Here, we summarize the recent knowledge on BSEP by covering its transport properties, 
cellular localization, regulation, and major mutations/polymorphisms, as well as the 
hereditary and acquired diseases associated with BSEP dysfunction. We discuss the different 
model expression systems employed to understand the function of the BSEP variants, their 
drug interactions, and the contemporary therapeutic interventions. 
Expert opinion 
The limitations of the available model expression systems for BSEP result in 
controversial conclusions, and obstruct our deeper insight into BSEP deficiencies and BSEP-
related drug interactions. The knowledge originating from different methodologies, such as 
clinical studies, molecular genetics, as well as in vitro and in silico modeling, should be 
integrated and harmonized. Increasing availability of robust molecular biological tools and 
our better understanding of the mechanism of BSEP deficiencies should make the 
personalized, mutation-based therapeutic interventions more attainable. 
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Abbreviations: 
4-PBA 4-phenylbutyrate 
ABC ATP-Binding Cassette 
BRIC2 benign recurrent intrahepatic cholestasis type II 
BSEP/ABCB11 bile salt export pump 
DBD 4-N,N-dimethylaminosulfonyl-2,1,3-benzoxadiazole 
DILI drug-induced liver injury 
ESE exonic splicing enhancers 
ESS exonic splicing silencer 
FDA U.S. Food and Drug Administration 
FXR farnesoid X receptor 
HCC hepatocellular carcinoma 
ICP intrahepatic cholestasis of pregnancy 
MDR1 multidrug resistance protein 1 (P-gp) 
NBD nucleotide binding domain 
NTCP sodium-dependent bile salt uptake transporter (SLC10A1) 
OATPs organic anion transporters 
PC phosphatidyl choline 
PFIC2 progressive familial intrahepatic cholestasis type II 
P-gp P-glycoprotein (MDR1) 
QSAR quantitative structure–activity relationship 
SNP single nucleotide polymorphism 
Spgp sister of P-glycoprotein 
TMD transmembrane domain 
TMH transmembrane helix 
UDCA ursodeoxycholic acid 
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1. Introduction 
The bile salt export pump (BSEP) is a liver resident transporter protein, which plays an 
essential role in the enterohepatic circulation of the bile salts [1, 2]. BSEP belongs to the 
ATP-Binding Cassette (ABC) protein family, the members of which are integral membrane 
proteins, defined by the existence of conserved sequences, the Walker A, Walker B, and the 
so called ABC signature motif. ABC transporters are composed of transmembrane domains 
(TMDs) containing typically 5-6 transmembrane helices (TMHs) and cytoplasmic ABC units 
or nucleotide binding domains (NBDs), which are responsible for the binding and hydrolysis 
of ATP, the energy of which is utilized for the translocations of transported substrates across 
the membrane. ABC proteins are present in all sorts of organisms; both uptake and efflux 
transporters (importers and exporters) can be found in prokaryotes, whereas ABC transporters 
in eukaryote plasma membrane are exclusively exporters.  
The 48 human ABC proteins (classified into seven subfamilies, ranging from ABCA to 
ABCG) possess very different transport characteristics and contribute to diverse physiological 
functions, including detoxification, antigen presentation, and secretory processes. A group of 
ABC transporters, expressed in various physiological barriers and sanctuary sites of the body, 
form a complex network constituting an innate defense mechanism against endo- and 
xenobiotics, which is called the chemoimmunity system [3]. An important component of this 
defense system is the hepatic transport network, in which the bile salt export pump plays a 
pivotal role. 
In this paper we give an overview on the current knowledge on the hepatic ABC 
transporter, BSEP. We discuss the model systems employed to understand its functional 
properties, the diseases associated with its malfunction, as well as the conventional and 
recently introduced therapies to cure these disorders. 
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2. Architecture, localization, and transport function of the bile salt export pump 
BSEP (or ABCB11) belongs to the B subfamily of ABC transporters. It shows high 
sequence and structural homology to the multidrug transporter P-glycoprotein (P-gp, MDR1, 
ABCB1), thus, BSEP was originally named sister of P-gp or Spgp [4]. Similar to P-
glycoprotein, BSEP possesses a canonical ABC transporter membrane topology, having a 
domain order of TMD1-NBD1-TMD2-NBD2, as well as containing a large, heavily 
glycosylated extracellular loop in the first transmembrane domain, between TMH1 and 
TMH2. As a basic building principle of all other ABC transporters, organization of domains 
shows an internal dimeric arrangement; the two TMDs constitute a common structure in the 
membrane, as well as the two nucleotide binding pockets are composite sites jointly formed 
by the Walker A and Walker B motifs from one NBD with the ABC signature motif from the 
other NBD. It is generally accepted that intracellular coupling helices located between TMDs 
and NBDs convert the energy from ATP hydrolysis to conformational changes in the TMDs, 
thereby allowing substrate translocation. In BSEP the coupling helices have not been 
examined in detail, but their presence can be assumed on the basis of the high sequence 
homology to P-glycoprotein, in which these interacting helices have already been identified 
[5]. 
In recent years, higher resolution crystal structures of several ABC exporters have 
become available. These include the bacterial SAV1866 [6], the murine MDR1a/ABCB1 [7, 
8], and the human ABCB10 [9] transporters. Thus far the structure of BSEP has not been 
resolved, although homology models have been generated based on the crystal structures of 
SAV1866 and mouse MDR1a [10, 11]. 
Unlike P-glycoprotein, which is present in a wide range of cell types, BSEP is selectively 
expressed in hepatocytes [4]. Although low levels of mRNA and protein expression were 
detected in the testis and adrenal gland of humans [12, 13], the function of BSEP in these 
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tissues is unknown. BSEP is specifically expressed in the apical (canalicular) membrane of 
hepatocytes, but a substantial amount of BSEP can also be found in subapical vesicles [14, 
15]. The apical surfaces of adjacent hepatocytes form a microscopic tube-like structure, the 
bile canaliculus, which is sealed by tight junctions (see Fig. 1). The bile canaliculi are 
interconnected, forming a complex tubular network, the smallest branches of the biliary tree 
of the liver. A detailed biochemical study demonstrated that under basal conditions only a 
small portion of BSEP resides in the canalicular membrane, the larger part is located in the 
intracellular vesicular pool, from which it can be rapidly mobilized to the cell surface [16]. 
Following biosynthesis most canalicular membrane proteins, such as the transferrin receptor, 
are targeted from the Golgi apparatus to the basolateral surface first, then transcytosed to the 
canalicular membrane compartment. However, newly synthetized BSEP is delivered directly 
to the intracellular pool and then to the canalicular surface [16]. It has also been demonstrated 
that BSEP undergoes continuous cycling between the canalicular membrane and the rab11a-
positive recycling endosomal pool [17]. 
As most ABC transporters, BSEP is an active transporter powered by ATP binding and 
hydrolysis. Contrary to P-glycoprotein, which transports a wide variety of compounds, BSEP 
exports a restricted number of molecules, predominantly monovalent taurine- and glycine-
conjugated bile salts [18]. It has been proposed that unconjugated bile salts are also BSEP 
substrates; however, these molecules are probably transported only at very low rate (see in 
[19]). Non-bile acid compounds, such as pravastatin and fexofenadine, have been reported to 
be transported by the human BSEP [20, 21]. In addition, it has been suggested that vinblastine 
and calcein-AM are substrates of the mouse BSEP (mBSEP) [22]. However, these results 
should be taken with caution, because these compounds are good MDR1 substrates, and 
MDR1 can easily be up-regulated in many cellular model systems. Although slight species 
differences in the substrate recognition of the human, rat, canine, and feline BSEP have been 
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reported [23, 24], the major transport function of this transporter seems to be evolutionary 
conserved [19]. 
3. Physiological role and regulation of BSEP  
A large fraction of bile constituents are continuously cycled in the enterohepatic 
circulation. About 95% of the bile salts travel through this cycle. A critical step in this process 
is the hepatic secretion of the bile, which is conducted by the transporters residing in the 
canalicular membrane of hepatocytes [2]. BSEP expels bile salts to the bile canaliculi, 
whereas MDR3/ABCB4 flips phosphatidyl choline (PC) to the outer leaflet of the membrane, 
resulting in net efflux of PC. The ABCG5/G8 heterodimer exports cholesterol to mixed 
micelles and PC vesicles. Other canalicular transporters including ATP8B1/FIC1, 
MRP2/ABCC2, MDR1/ABCB1, ABCG2, and the chloride-bicarbonate anion exchanger 2 
(AE2) also contribute to the composition of bile by retaining aminophospholipids and 
exporting divalent bile salts, anionic conjugates, organic cations, glutathione, and bicarbonate 
to the bile (reviewed in [2, 25]). It has been proposed that ABCG2 is capable of bile acid 
transport [26], however, its physiological role, especially in the liver, is debated as discussed 
in detail in Ref. [2]. The basolateral (sinusoidal) transporters for bile acids include various 
solute carriers, such as NTCP, OATP1B1, OATP1B3, and OSTα/β [27, 28]; export pumps, 
such as MRP3/ABCC3, MRP4/ABCC3 [29, 30]. NTCP and the OATPs responsible for the 
uptake of bile acids from the sinusoidal space into the hepatocytes, whereas MRP3, MRP4 
and OSTα/β mediate a reverse transport, when it becomes necessary (see Fig. 1). 
Export of bile salts driven by BSEP was shown to be the rate limiting step in bile 
secretion [1]. Thus, the expression and function of BSEP is a critical determinant of the 
enterohepatic circulation of the bile salts. The expression of BSEP is under the control of the 
farnesoid X receptor (FXR), a bile acid sensor, which forms heterodimer with RXRα upon 
activation, and consequently binds to FXR response element in the promoter of BSEP [31]. 
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This FXR-mediated transcriptional activation can be further modified by other nuclear 
receptor co-activating proteins including ASCOM, CARM1, and SRC2 [32]. Moreover, FXR-
independent transcriptional regulation of BSEP involves LRH1, NRF2, and PXR [32].  
In addition to the transcriptional control, the cell surface expression of BSEP can be 
rapidly modulated by mobilization of the intrahepatic, BSEP-containing vesicles, or inversely 
by controlling the internalization of the transporter from the canalicular membrane. This 
redistribution between the endosomal pool and the cell surface provides a fine-tuned 
regulatory mechanism, reacting promptly to the demand for the bile secretory capacity. The 
taurine-conjugated bile salt, taurocholate was shown to act not only as a bile constituent but 
also as a signaling molecule, which can trigger the delivery of BSEP to the canalicular 
membrane [16]. Recently, we have demonstrated that taurocholate-stimulated canalicular 
trafficking of BSEP is controlled by a signaling pathway that involves the 
EPAC/LKB1/AMPK kinase cascade [33]. In addition to taurocholate, cAMP also promotes 
BSEP trafficking to the canalicular surface by an alternative, PKA-dependent mechanism [16, 
33]. PI3K has been shown to participate in the taurocholate-mediated redistribution of BSEP 
but not in the cAMP-stimulated response [34]. Another bile salt, tauroursodeoxycholate has 
been demonstrated to stimulate delivery of BSEP from the Golgi to the cell surface through 
the activation of p38 MAP kinase [35]. The presence and the half-life time of BSEP on the 
cell surface are determined not only by the delivery rate, but also by anchoring and 
internalization mechanisms. Numerous regulatory proteins such as cortactin, HAX-1, EPS15, 
AP-2, and IP3-receptor II have been suggested to participate in this process [36]. 
Canalicular ABC transporters including MDR1, MRP2, ABCG5, and BSEP are localized 
in bile salt-resistant, cholesterol- and sphingomyelin-rich microdomains of the hepatocyte 
canalicular membrane [37, 38]. As previously shown for MDR1, MRP2, and ABCG2 [39-42], 
the activity of BSEP is modulated by the cholesterol content of the membrane [43, 44]. 
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However, cholesterol increases only the transport capacity (Vmax) of BSEP, without affecting 
the affinity for the substrates (Km) [45]. This differs from what was observed with MRP2, 
where both Vmax and Km are modified by cholesterol. The exact mechanism how cholesterol 
modulates BSEP activity is unknown. Using a heterologous in vitro system, the 
phosphorylation of BSEP by PKCα has also been demonstrated [46], however, its 
physiological relevance remains to be clarified. 
Transporters in hepatocytes, including both canalicular and basolateral transport proteins, 
constitute a complex, coordinated system. Expression of the enzymes and transporters 
involved in the bile salt synthesis, uptake, and secretion is concertedly regulated. In addition, 
the function of transporters exporting other bile constituents is also essential for proper BSEP 
function. Even drug transporters can influence the function of BSEP by controlling of the 
distribution of compounds interacting with the transporter either on the intracellular or the 
intraluminal side. The latter is exemplified by the trans-inhibition of BSEP by estradiol-17β-
glucuronide or progesterone metabolites, which are exported by MRP2 to the canalicular 
lumen [47, 48]. 
4. Human diseases associated with BSEP mutations 
A large number of mutations and polymorphisms in the BSEP gene have been identified, 
which either cause hereditary liver diseases, or represent susceptibility factor for the 
development of various conditions affecting mainly the liver [11, 36, 49-53]. An up-to-date 
database summarizes the available information on the mutant variants of ABC transporters 
including BSEP (see http://abcmutations.hegelab.org/) [54]. All regions of BSEP can be 
affected, but the hot spots for mutations are the NBDs and the cytoplasmic loops. BSEP 
polymorphisms are ethnic dependent and usually rare, with the exception of the V444A and 
M677V variants, which exhibit allele frequencies ranging 50-93% and 0-15%, respectively, 
depending on the ethnic background [51]. 
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Hereditary liver diseases caused by loss of function mutations in BSEP include the 
progressive familial intrahepatic cholestasis type II (PFIC2) and the benign recurrent 
intrahepatic cholestasis type II (BRIC2). In these syndromes impaired bile salt secretion 
caused by the lack or insufficient amount of functioning BSEP in the canalicular membrane 
leads to intrahepatic cholestasis characterized by diminished bile production, reduced bile 
flow, and intrahepatic accumulation of toxic bile salts, concomitant with high plasma levels of 
bile salts and bilirubin. PFIC2 is an early onset disease with rapid progression frequently 
leading to end-stage liver complications before adulthood, whereas BRIC2 is characterized by 
recurrent episodes of cholestasis and consequent pruritus without substantial liver damage in 
most cases. PFIC2 patients are also susceptible to development of pediatric hepatocellular 
carcinoma (HCC) and cholangiocarcinoma [55, 56]. Several mutations in BSEP have been 
shown to be responsible for PFIC2 and/or BRIC2 (see Table 1). These include the relatively 
frequent E297G and D482G variants, which are present in 58% of European PFIC2 patients 
[49]. 
The intrahepatic cholestasis of pregnancy (ICP) is a transient form of cholestatic liver 
diseases manifesting usually in the third trimester of pregnancy, and characterized by elevated 
serum bile acid levels, variable pruritus, fetal distress and increased risk for preterm delivery. 
Numerous polymorphisms and mutations inBSEP, including the common V444A variant, 
have been identified as susceptibility factor for ICP [11, 51, 57-61]; however, the mechanism 
how these variants contribute to the progression of ICP is unclear. High levels of estrogens 
and progesterone have been proposed to be responsible for the trans-inhibition of BSEP in the 
later stage of pregnancy [48], but transcriptional repression of BSEP expression by 17β-
estradiol and epiallopregnanolone sulfate has recently been demonstrated, providing an 
alternative model for the development of ICP [62].  
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Substantial interindividual variability has been observed in the BSEP expression at both 
mRNA and protein levels even in healthy individuals [51, 63]. The frequent V444A variant 
was associated with low expression levels. Patients with BSEP-deficiencies usually exhibit 
reduced canalicular expression of BSEP. Staining with anti-BSEP antibodies of liver tissue 
samples combined with genotyping is a powerful method to evaluate the disorder [64, 65]. 
Several studies reported recurrence of intrahepatic cholestasis due to the autoantibodies raised 
against BSEP after liver transplantation. The antibody originated from one of these cases 
recognizes an extracellular epitope of the human BSEP, moreover, suppresses its function 
[66], providing an ideal tool for assessment of BSEP at the protein level. Inversely, the 
presence of autoimmune antibodies can be detected by canalicular antibody deposits in liver 
tissue samples subjected to the patients’ serum, which specificity can be subsequently verified 
by Western blot analysis [11]. 
Besides estrogens and progesterone metabolites, numerous drugs, including rifampicin, 
troglitazone, nefazodone, glibenclamide, cyclosporin A, and bosentan, have been shown to 
block BSEP function, thus, a cholestatic form of drug-induced liver injury (DILI) can develop 
upon treatment with these agents [53, 67-69]. The efforts to predict drug interaction with 
BSEP will be discussed later; nevertheless, the contribution of genetic factors to drug-induced 
cholestasis is also unambiguous. The frequent V444A variant and numerous rare mutations 
have been identified as risk factors for cholestatic DILI [52, 60, 61]. In addition to ICP and 
DILI, numerous BSEP variants are associated with several other liver diseases including 
primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), primary intrahepatic 
stones, gallstone disease, and neonatal cholestasis [70-72]. Despite the substantial amount of 
genomic data accumulated in the last decade, the etiological role of these BSEP mutations and 
SNPs in the acquired cholestatic liver diseases remains to be established. 
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Although the association of BSEP mutations and polymorphisms with the above 
discussed liver diseases is clearly documented, the mechanisms how these mutations/SNPs 
lead to the syndromes are diverse and controversial. Mutations in the BSEP gene can result in 
defective bile salt secretion in several ways, which include reduced mRNA stability, protein 
misfolding and instability, loss of transport activity, as well as impaired trafficking to the 
canalicular surface. Nevertheless, a close correlation between the cell surface expression of 
BSEP and the clinical manifestation of PFIC2/BRIC2 has been demonstrated [73]. Even 
though the two most frequent disease-causing BSEP mutations (E297G and D482G) were 
extensively studied, the results are controversial. The discrepancies are likely stemmed from 
the differences in the applied experimental arrangements, including the different origin of 
BSEP in terms of species (human, rat, or mouse), and diversity of heterologous expression 
systems used for trafficking and/or transport studies. Table 1 summarizes the identified 
defects caused by various BSEP mutations and SNPs, specifying the major features of the 
used model systems.  
5. Assessments of expression and function of BSEP 
Reliable assay systems detecting BSEP expression, localization and function are crucial 
for dependable diagnosis and understanding the mechanisms of BSEP-related diseased 
conditions. The various detection methods assessing BSEP expression at the protein level 
with the help of anti-BSEP antibodies were discussed in the previous Section. Another 
approach to investigate the basis of reduced expression of BSEP is the so-called minigene 
system, which determines aberrations at the RNA level [50]. This method revealed abnormal 
pre-mRNA splicing in a considerable number of mutations and SNPs in the BSEP gene.  
Different in vitro model systems are used to evaluate BSEP expression and function; 
however, the results have to be interpreted carefully because of the complexity of bile salt 
circulation, drug metabolism, and transport systems. Some models aim at investigating certain 
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specific properties of the transporter, whereas others try to build a more complex net of 
transporters in a cellular context for measuring vectorial transport of bile salts. Variance in the 
applied cellular models may affect the intracellular fate of the studied BSEP variant. The 
robust Sf9 insect cell expression system commonly used for transport studies is relatively 
tolerant of protein misfolding, whereas mammalian cells, especially polarized epithelial cells 
are more sensitive to folding problems, thus, are also suitable for studying trafficking defects. 
However, it should be noted that the trafficking machinery of the commonly used model cells, 
such as MDCK, HEK293, and HepG2, can considerably differ from that of the hepatocytes, 
the authentic cell type. This is exemplified by the fact that the stimulatory effect of 
taurocholate on BSEP trafficking can be observed in vivo and in isolated hepatocytes [16, 33], 
but not in Wif-B9 liver model cells [17]. 
Species differences add an extra complication, since dissimilarities between the 
properties of human and non-human BSEP may result in discrepancies in in vitro model 
systems. Common laboratory model animals, such as rats and mice, exhibit significant 
differences in bile composition, bile salt levels, and regulation as compared to humans. The 
ratio of glycine to taurine conjugates in humans is 3:1 and the prevalent form is 
chenodeoxycholate. The ratio is the reverse in rodents, and the bile composition is dominated 
by more hydrophilic bile salts [74], making rodents less susceptible to cholestatic conditions. 
Human and rodent BSEP expressed in heterologous systems exhibit different affinity for 
various bile salts. The highest affinity substrate of the human BSEP is taurocholate, whereas 
the preferred substrate of rodent BSEP is taurochenodeoxycholate [14, 18]. It should be noted 
that affinities for monovalent bile acid conjugates are very close, and the determined affinity 
orders vary to some extent with the experimental conditions (see more details in [19]). Feline 
and canine BSEP proteins, sharing 91.2% homology with human BSEP, prefer taurine-
conjugated bile acid over glycocholic acid, and have lower affinity for unconjugated cholic 
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acid [24]. Although the affinities of BSEP for different substrates are slightly different, the 
substrate spectrum in general is fairly conserved [19]. Therefore, both human and rodent 
BSEP are used in in vitro assay systems to study transporter-drug interactions. Human BSEP 
is regularly employed in the vesicular transport measurements; whereas mouse or rat BSEP is 
preferred in the ATPase assay, since rodent versions of BSEP possess higher ATPase 
activities than the human counterpart [75]. Since the ATP activity of either BSEP variant is 
very low as compared to that of the multidrug transporters, the results obtained from these 
assays should be interpreted cautiously, because of the high risk for false positive and 
negative hits for inhibitors and stimulators, respectively. 
Contrary to the human clinical experience, BSEP knockout mice have no marked liver 
disease only when challenged with high cholate diet [76]. These animals still secrete 30% of 
normal bile salts into bile, predominantly tauromuricholate and tetrahydroxylated bile salts, 
and exhibit elevated P-gp expression, which may help to prevent disease development [77, 
78]. An interesting model option is mBSEP overexpression in the liver of mice [79]. These 
animals display enhanced biliary lipid (phospholipid and cholesterol) secretion paralleled with 
an increased bile salt output.  
Vectorial transport of labelled bile salts, measured in rat or human sandwich-cultured 
hepatocytes represents a more complex model system. It should be noted that similar to the 
case of BSEP, other canalicular efflux and basolateral uptake transporters involved in the bile 
salt transport also show species differences [80, 81]. Modeling the differences in the transport 
and drug metabolic pathways between the human and animal hepatocytes may help to 
increase the reliability of animal-derived hepatocyte models in drug interaction tests. 
The causes of drug-induced liver toxicity are diverse, and only a minor portion of DILI is 
linked to BSEP. As mentioned earlier several agents including even high-profile drugs have 
been shown to induce liver toxicity through BSEP inhibition. A comprehensive study found 
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that 38 out of 200 common drugs inhibited taurocholate transport with an IC50 of less than 
100 µM [82]. Several in vitro assay systems are available to evaluate potential drug 
interactions with BSEP. Insect cell membrane vesicles containing recombinant BSEP provide 
a rapid and cost-effective approach. Ki values determined by this method showed reasonably 
good correlation with the results of vectorial transport assays and in vivo data [19]. The 
sensitivity of the Sf9 cell-based assay can be increased by cholesterol loading of the insect 
cell membranes, which are normally intrinsically poor in cholesterol [43, 45]. Cholesterol 
treatment increases the Vmax but not the Km values for various bile salts, with the exception of 
glycochenodeoxycholate. Using this assay system for screening large compound libraries, 
several chemically different compounds were identified as possible BSEP inhibitors. Positive 
hits can be subsequently checked in more complex in vitro systems, such as the vectorial 
assays of cell monolayers using primary hepatocyte cultures or engineered model cells 
(MDCK or LLC-PK1) expressing BSEP and a bile salt uptake transporter, e.g., NTCP [83].  
Primary hepatocyte cultures represent the most complex in vitro systems having the full 
set of bile salt transport systems together with the entire drug metabolic machinery, although 
in this case not only direct drug inhibitions but also the effects of drug metabolites are 
measured. In vesicular assays the drugs reach the transporter primarily from the cytoplasmic 
side, since inverted membrane vesicles are used. In contrast, in vectorial systems drugs can be 
applied either from the apical or the basolateral surface, which allows deciphering the 
sidedness of the drug interaction. This is how trans-inhibition of BSEP by estradiol-17β-
glucuronide or progesterone metabolites has been revealed [47, 48]. Nevertheless, most 
inhibitory drugs are thought to act from the cytoplasmic side of BSEP. It should be noted that 
the sidedness cannot be unambiguously determine in many cases, since several therapeutic 
agents are lipophilic, thereby easily penetrate the cell membrane, and can reach even 
transmembrane drug binding sites, as shown previously for P-gp. In addition, vectorial 
16 
 
transport systems allow combined administration of bile acids and tested drugs, mimicking 
the drug-induced cholestasis. For example ritonavir, cyclosporin A, and simvastatin have been 
shown to become toxic only in the presence of bile acids, suggesting certain cooperativity 
[84]. These results should, however, be interpreted cautiously, because the high levels of bile 
acids far from physiological concentrations (200-fold of normal level), can alter membrane 
lipid structure by themselves. 
Another important issue is the type of labeled substrates employed in the in vitro 
transport assays. A favored test compound is taurocholate, and most studies use radiolabeled 
substrates. For economical and safety reasons fluorescently labeled bile salts have also been 
developed. However, most fluorophores were shown interfere with the transport by 
substantially altering the size or hydrophobicity of the substrate. The aminofluorescein-tagged 
bile acids, such as chenodeoxycholylglycyl-amido-fluorescein and cholylglycyl-amido-
fluorescein are substrates for both NTCP and BSEP, but not as good as taurocholate [83]. Not 
only the size of the fluorophore, but its position on the substrate molecule is also important. 
Taurocholate conjugated with 4-N,N-dimethylaminosulfonyl-2,1,3-benzoxadiazole (DBD) on 
the side chain was successfully applied in insect cell vesicular and vectorial transport assays 
[85, 86].  
6. In silico models for predictions of cholestatic effects of drugs  
Various methods have been established to predict drug interactions with BSEP, as well as 
to evaluate mRNA and protein stability problems. ESE (exonic splicing enhancers) and ESS 
(exonic splicing silencer) prediction programs are used to identify nucleotide substitutions 
that could alter mRNA splicing [50]. Discrepancies in the experimental methods and the in 
silico predictions have made these estimations ambiguous thus far.  
More sophisticated are the structure-based models for drug interactions, but no crystal 
structure is available for BSEP. Homology models for ABC exporters were generated on the 
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basis of the few known crystal structures available, mainly that of the bacterial multidrug 
exporter, Sav1866 [6]. Recently, the mouse P-gp has been crystallized, and its structure has 
been resolved at a sufficiently good resolution. Since BSEP exhibits high sequence similarity 
to P-gp, its structure provides a better basis for homology modeling. It should be noted, 
however, that homology modeling always bears some uncertainties and especially the 
transmembrane regions in BSEP cannot be modeled reliably. Despite these problems, 
homology model was used to identify the extracellular epitope recognized by the anti-BSEP 
antibody mentioned above [66]. 
Some drug interaction prediction methods are based on ligand characteristics, such as 
QSAR (structure activity model for ligands), pharmacophore models, and non-linear SPECS. 
These methods are established and validated in high throughput BSEP in vitro drug 
interaction datasets, which were significantly expanded recently [10, 67, 68, 84, 87-91]. 
A comprehensive, membrane vesicle-based study investigated a set of 624 compounds 
for BSEP inhibition [10]. Based on the physicochemical properties of the identified blockers, 
the inhibitory effect showed strong correlation with the lipophilicity and molecular size. It 
should, however, be noted that the IC50 threshold for significant BSEP inhibition was set to 
300 µM in this study, which may overestimate the number of blockers. Another study, using 
vesicular transport assay, identified 86 BSEP inhibitors out of 250 test compounds [87]. 
QSAR modeling, here too, demonstrated a strong correlation between the lipophilicity and 
BSEP inhibition, whereas positive charge prevented the inhibitory effect. About 60% of the 
FDA-approved drugs, identified as BSEP inhibitors in this study, carry the risk for DILI 
according to the drug labels. Correlation between the severity of DILI and the inhibitory 
effect of the drugs on the taurocholate transport was also demonstrated using human 
hepatocyte sandwich cultures [87]. 
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Similarly, the frequency and severity of bile acid-mediated DILI in connection with 
BSEP inhibition are predicted by using DILIsym, a multi-scale mechanistic mathematical 
model (http://www.dilisym.com). A great amelioration is the incorporation of bile acid 
dynamics in the DILIsym [92], thus, the model includes not only the metabolic pathways, 
mitochondrial toxicity, key transporters, etc., but also the synthesis, uptake, recirculation, 
efflux, and hepatotoxicity of bile acids. This complex approach may help to reduce 
discrepancies originated from species differences as well as from in vitro and in vivo 
experimental data, thereby allowing improved prediction of BSEP-related DILI [92]. 
For its straightforwardness the pharmacophore modeling is commonly used for drug 
interaction prediction, however, the promiscuous drug binding site of ABC transporters also 
makes this approach challenging. Several models have been developed on congeneric series, 
which restricts their applicability to structurally related compounds [88]. A recent 3D 
pharmacophore model aims at identifying functional groups common in BSEP-inhibiting 
molecules along with fixed intramolecular distances between interacting motifs [93]. This 
model is based on the inhibitory effect of test compounds with an IC50 value of 50 µM or less, 
which was determined by human BSEP-containing membrane vesicles. The importance of 
hydrogen bond acceptors, anionic and loosely defined aromatic features were established as 
BSEP inhibitor pharmacophores, in which the exclusion volume has proven to be also 
important. This pharmacophore was subsequently confirmed with a set of 59 molecules. 
Since latest surveys concluded that MRP4 inhibition has a significant impact in 
development of DILI, a new pharmacophore model has recently been developed that 
combines BSEP and MRP4 inhibitions [90]. Since MRP4 and BSEP have partially 
overlapping inhibitor profiles, modeling has to focus on both common and distinct features of 
these two sets of compounds. Welch et al. have built a Bayesian model, which has an 
increased predictive value as compared to other methods [91]. Their model underline the 
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importance of high molecular weight, hydrophobicity, certain rotatable bonds and the 
aromatic features, which is in agreement with the conclusions of previous studies [87, 93]. 
In summary, all the above discussed models and simulations have significant predictive 
potential, however, the complexity of bile acid metabolism and promiscuity of the potential 
drug binding site of BSEP create substantial uncertainties and require careful interpretation of 
predictions. 
7. Pharmacological correction of BSEP deficiencies 
Diseases associated with BSEP mutations and SNPs as well as the manifestation of these 
conditions are highly diverse, thus, therapeutic approaches also range from symptomatic 
treatment to major surgical interventions. The most severe form of BSEP deficiencies, PFIC2 
is primarily treated surgically, which includes external or internal partial biliary diversion, 
ileal bypass, and even liver transplantation. Interestingly, the outcome of these surgical 
treatments to some extent depends on mutation type. For instance, the E297G and D482G 
mutations were associated with better prognosis after partial biliary external diversion [94]. 
Similarly, nonsense and splice site mutations were more frequent in cases, when PFIC 
phenotype recurred after liver transplantation, due to the emergence of anti-BSEP antibodies 
[65]. 
Numerous mutations and polymorphisms in the BSEP gene have been demonstrated to 
result in reduced mRNA level [50]. Transcriptional activation by nuclear receptor agonists, 
such as FXR ligands, provides a novel therapeutic approach to correct these deficiencies 
(reviewed in [32]). In addition to FXR agonists, targeting of PXR, CAR, PPARα and PPARγ, 
as well as the vitamin D and glucocorticoid receptors may also assist to restore the balance of 
bile salt metabolism in BSEP-associated liver diseases. A recent clinical report demonstrated 
unexpected improvement in the bile acid levels and relief of symptoms in PFIC2 patients in 
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response to steroid treatment [95], offering a new perspective for BSEP-deficiency therapy, 
although the mechanism of action remains to be investigated. 
Ursodeoxycholic acid (UDCA) is a commonly used medication in various cholestatic 
liver diseases including PFIC2, BRIC2 and ICP. UDCA significantly reduces pruritus and 
improves clinical parameters; however, its beneficial effect falls short in numerous patients. 
Genetic factors, such as the type of BSEP mutations, can be responsible for the ambiguous 
therapy outcome, although this has not yet been demonstrated by comprehensive association 
analyses. Several mechanisms have been suggested to explain the effectiveness of UDCA. In 
the most commonly accepted view the non-toxic UDCA dilutes the cytotoxic bile salts in the 
endogenous bile acid reservoir, thus improving the clinical parameters. It has also been 
proposed that UDCA stimulates BSEP and MRP2 transcription, stabilizes the hepatocyte 
membrane, inhibits hepatocyte apoptosis, and promotes bile flow via cholehepatic shunting. 
The effect of ursodeoxycholic acids on the trafficking of BSEP is also controversial. Taurine-
conjugated UDCA promotes BSEP delivery to the canalicular surface [15, 35], whereas 
UDCA have been shown to reduce BSEP internalization [96]. Nevertheless, the efficacy of 
the treatment was dependent on the BSEP mutation. A recent study demonstrated partial 
correction of impaired trafficking of BSEP with PFIC2-causing mutations by UDCA [97]. 
Using chemical chaperones or correctors has recently become a rapidly developing field 
in the therapy of diseases associated with mutations in ABC transporter genes [98]. 
Systematic screening revealed a series of small molecules that can rescue the impaired 
trafficking of misfolded CFTR-ΔF508, causing cystic fibrosis, the most frequent lethal 
inherited disease. Similar advances were achieved by in vitro and in vivo studies with ABCG2 
and ABCC6 in connection with gout and pseudoxanthoma elasticum, respectively [99, 100], 
although clinical studies have not yet performed in these diseases. The major corrector 
molecule used in these experiments is the 4-phenylbutyrate (4-PBA), an FDA-approved drug 
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for thalassemia and urea cycle disorders. This agent was found to increase cell surface 
expression of the BSEP mutants, D482G and E297G in vitro, as well as enhance bile salt 
excretion in vivo [73, 101]. Besides 4-PBA, bile salts were shown to act as pharmacological 
corrector stimulating the delivery of BSEP-E297G to the cell surface [102]. Even more 
exciting are the recent clinical data demonstrating that high-dose 4-PBA treatment can 
markedly improve the clinical parameters of PFIC2 patients bearing trafficking defect 
mutations in BSEP such as G982R, T1210P, R1128C, or R1231Q [97, 103, 104]. For many of 
these cases partial correction of canalicular expression of the mutated BSEP has also been 
demonstrated.  
8. Expert opinion 
The liver-resident membrane transporter protein, the bile salt export pump (BSEP) is a 
key component of the enterohepatic circulation. It controls the extrusion of monovalent bile 
salts into the bile canaliculi, the microscopic tubular structures formed by adjacent 
hepatocytes (see Fig. 1), which collect and direct bile to bile ducts. Since the export of bile 
salts is the rate limiting step in bile secretion [1], the transporter mediating this process is of 
great physiological and pathophysiological importance. Many ABC transporters have 
overlapping substrate recognition, thus, when one of them is dysfunctional, other ones can 
compensate for the impaired function. However, no backup system for bile salt excretion is 
available; therefore, loss of function of BSEP necessarily leads to severe consequences. 
Although basolateral transport systems in hepatocytes can weaken this effect, deficient 
canalicular secretion results in accumulation of bile salts in the hepatocytes (intrahepatic 
cholestasis). Most bile salts are strong detergents, thus have profound cytotoxic effect. Their 
intrahepatic accumulation leads to hepatocellular necrosis, chronic inflammation, fibrosis, and 
ultimately liver failure. 
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Diseases caused by BSEP deficiency range from transient, mild conditions to early onset, 
fatal liver disorders. Manifestation of the disease greatly depends on the type of BSEP 
dysfunction. Several causes can lead to loss of BSEP function. Mutations in BSEP can result 
in complete loss of expression, decreased mRNA/protein stability, impaired trafficking, or 
diminished transport. Hormones, drugs and drug metabolites can also interfere with the 
transport function of BSEP. Nevertheless, the current knowledge on the mechanism for BSEP 
deficiencies is rather controversial (see Table 1). In numerous cases a combination of 
hereditary and acquired factors results in the dysfunction of the transporter. For instance, 
several polymorphisms in BSEP are suggested to be susceptibility factors for ICP or DILI.  
Understanding the mechanism how mutations and polymorphisms lead to BSEP 
deficiency and ultimately to diseased conditions is a crucial prerequisite to develop efficient 
and cost-effective therapeutic interventions. Model systems, including ex vivo, in vitro, and in 
silico methods provide not only a great opportunity to decipher the disease mechanisms, but 
also offer screening systems for interacting drugs. The increasing availability of robust 
molecular biology techniques makes possible to screen for mutations in a large scale and to 
elucidate complex transcriptional events, giving the opportunity to understand even 
multifactorial conditions. However, it should be noted that extensive database analyses, 
clinical studies, especially case reports, as well as in vitro and in silico models still represent 
different worlds of perception. This phenomenon is not specific for the cholestatic liver 
diseases, but similar scenario has evolved in other biomedical fields, including the even more 
complex areas, such as the tumor biology.  
A critical requirement for our better understanding of BSEP deficiencies is the refinement 
of the available model systems. Although numerous features of bile metabolism seem to be 
evolutionary conserved, even slight differences between the species may result in large 
deviations in consequences. This is exemplified by the fact that rodents are less susceptible to 
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cholestatic conditions due to the predominance of more hydrophilic bile salts as compared to 
humans. Results of trafficking studies should also be interpreted carefully, since targeting 
machinery of the employed model systems may differ from that of hepatocytes, thus, cellular 
routing of the mutated/polymorphic BSEP variants as well as the modulatory effect of 
pharmacological agents on their trafficking may also differ. 
An exciting new perspective has been opened by the recent application of 
pharmacological correctors in PFIC2 patients. Many mutations associated with severe BSEP 
deficiencies cause trafficking defect, resulting in reduced plasma membrane expression of the 
transporter (see Table 1). If the transport capability is at least partially preserved, 
pharmacological chaperones may correct this type of BSEP deficiencies. Recently, 
encouraging clinical studies reported improvement of the clinical status of PFIC2 patients 
upon 4-PBA treatment [97, 103, 104]. However, progress was achieved only with a very high 
dose of drug, and the reported improvements were sometimes transient. 
In conclusion, further efforts should be made to improve the model systems to make them 
more reliable and better representing the human physiological and pathological conditions. 
Evidently, there is a need for a change in our perception of BSEP-related disorders. We 
should integrate the experiences of the clinical studies, the vast information generated by 
contemporary molecular genetics, as well as the results of ex vivo, in vitro and in silico 
modeling. Only this integrative approach can make mutation-specific, personalized 
therapeutic interventions possible to cure BSEP-associated cholestatic liver diseases. 
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Annotations 
* Ref. 4. Child S. et al. 1995 – This is a historic milestone paper reporting the identification of 
BSEP. 
* Ref. 16. Kipp H et al. 2001 – The large intracellular reservoir of BSEP, as well as its 
mobilization upon taurocholate and cAMP are reported in this paper. 
* Ref. 18. Byrne JA et al. 2002 – The basic characteristics and major transport properties of 
BSEP are summarized in this classical paper. 
* Ref. 25. Trauner M and Boyer JL 2003 – This is one of the most comprehensive reviews on 
BSEP, which covers all the important aspects of this medically important transporter. 
** Ref. 49. Strautnieks SS et al. 2008 – A detailed genetic analysis of European families that 
are affected with PFIC2. This paper is an important milestone in understanding of the genetic 
background of BSEP deficiencies. 
** Ref. 73. Lam P et al. 2007 – A detailed study of relevant mutations in BSEP, which 
demonstrates correlation between the manifestation of the disease and the cell surface 
expression of BSEP. This is also one of the first papers that shows the rescuing effect of 4-
PBA. 
** Ref. 77. Wang R et al. 2001 – A milestone paper in BSEP research, reporting the 
generation and phenotypic features of the BSEP knockout mouse. 
* Ref. 87. Pedersen JM et al. 2013 – A comprehensive study using different model systems to 
identify drugs that inhibit BSEP, thus having potential risk for drug-induced cholestatic liver 
disease. This study also demonstrates the benefits of sandwich-cultured human hepatocytes as 
in vitro assay system. 
** Ref. 101. Hayashi H, Sugiyama Y. 2007 – This is one of the first papers demonstrating 
that 4-PBA can promote delivery of mutant BSEP variants to the cell surface. 
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* Ref. 103. Gonzalez E et al. 2012 – The first clinical study demonstrating the beneficial 
effect of 4-PBA in a PFIC2 patient. 
* Ref. 105. Wang L et al. 2002 – The first comprehensive study that characterizes the most 
relevant BSEP mutations associated with PFIC2, using in vitro model systems. 
  
33 
 
Article highlights 
 A wide variety of cholestatic liver diseases is associated with the dysfunction of the bile 
salt export pump (BSEP), which normally mediates the secretion of monovalent bile salts 
into the bile. Manifestation of these disorders depends on the amount of functional BSEP 
on the cell surface. 
 BSEP-related diseases can be either inherited or acquired. The latter is frequently 
associated with mild mutations or polymorphisms in BSEP. Understanding how these 
mutations and/or drug interactions can lead to cholestatic liver disease is a prerequisite to 
develop efficient, cost-effective, and possibly mutation-based, personalized therapies.  
 Several human and non-human systems, including ex vivo, in vitro and in silico models, 
are employed to assess the mechanism of BSEP-related diseases and to predict the drug 
interactions. Most sophisticated model systems are based on the combination of various 
approaches. 
 Recently, patients with severe BSEP deficiency were successfully treated with 4-
phenylbutyrate, a pharmacological chaperone, which was able to restore at least partially 
the cell surface expression and the function of BSEP. 
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Legend for Figures and Tables 
Figure 1. Routing of bile salts in hepatocytes. Bile salts, arriving from the distal ileum 
through the hepatic portal vein to the hepatic sinusoids, are taken up by hepatocytes via the 
basolateral transporters, such as NTCP and OATPs. The recycled bile salts are reconjugated 
and extruded together with the newly synthetized bile salts by BSEP to the lumen of bile 
canaliculi, the miniature tubular structures, which are assembled from the apical membranes 
of adjacent hepatocytes, and sealed by tight junctions. The bile salts are then collected by the 
bile canaliculi and transferred to the bile ducts and subsequently to the gall bladder.  
Alternative routes for the canalicular bile salt export include MRP2 and supposedly ABCG2. 
The basolateral MRP3, MRP4, and OSTα/β transporters serve as an overflow system, 
mediating bile salt transport to the sinusoidal space, when needed. 
 
Table 1. BSEP mutations and polymorphisms associated with various cholestatic liver 
diseases. The defects in the trafficking, stability, and transport capability of BSEP are 
indicated as determined by different studies. The trafficking was considered abolished when 
no plasma membrane expression was found, whereas regarded as impaired, when the cell 
surface expression was reduced. The main features of the model systems used for in vitro 
assessments of the mutated BSEP are also listed. These include the species from which the 
transporter was originated, and the cell types used for trafficking or transport studies. n.d. – 
not determined 
   

 
 
Abbreviations: BRIC2, benign recurrent intrahepatic cholestasis type II; DILI, drug‐induced liver injury; ICP, intrahepatic cholestasis of 
pregnancy; PFIC2, progressive familial intrahepatic cholestasis type II 
*  also reported as susceptibility factors for ICP 
**  ambiguous due to low expression level 
***  found in a heterozygous PFIC2 patient 
Mutation/ 
SNP  Disease  Trafficking  Protein stability  Transport 
Model systems used for the studies 
Reference 
BSEP from   Trafficking  Transport 
E297G* 
PFIC2,  
BRIC2 
abolished  n.d.  abolished  rat  MDCK  Sf9  [105] 
impaired  shortend t1/2  in the membrane  normal
**  human  MDCK and HEK293  HEK293  [106] 
n.d.  n.d.  reduced  human  ‐  Sf9  [107] 
impaired  n.d.  abolished  rat  MDCK and HEK293  Sf9  [73]  
impaired  n.d.  reduced  rat  ‐  MDCK  [108] 
normal  n.d.  normal  human  HepG2  HeLa‐hNTCP  [51] 
n.d  elevated ubiqutination  n.d  human  MDCK  ‐  [109] 
impaired  rescued  n.d  human  CHO‐K1  ‐  [50] 
D482G* 
normal  n.d.  reduced  rat  MDCK  Sf9  [105] 
impaired  T sensitive mRNA  normal  mouse  HepG2  SF21  [110] 
abolished  n.d.  normal  human  MDCK   HEK293  [106] 
abolished  n.d.  normal  rat  MDCK and HEK293  Sf9  [73] 
impaired  shortend t1/2  reduced  rat  ‐  MDCK  [108] 
impaired  rescued  n.d.  rat  HEK293  ‐  [111] 
impaired  n.d.  abolished  rat  ‐  MDCK‐rNTCP  [96 64] 
n.d.  elevated ubiqutination  n.d. 
human BSEP in 
MDCK  ‐  ‐  [109] 
G982R 
abolished  n.d.  abolished  rat  MDCK  Sf9  [105] 
abolished  n.d.  n.d.  rat  HEK293  ‐  [111] 
impaired  n.d.  reduced  human  HepG2  HeLa‐hNTCP  [51] 
n.d.  n.d.  reduced  rat  ‐  MDCK‐rNTCP  [96 64] 
impaired  partially rescued  n.d.  rat  Can 10  ‐  [97] 
R1153C* 
abolished  n.d.  abolished  rat  MDCK  Sf9  [105] 
abolished  n.d.  abolished  rat  ‐  MDCK  [108] 
abolished  n.d.  n.d.  rat  HEK293  ‐  [111] 
impaired  n.d.  reduced  human  HepG2  HeLa‐hNTCP  [51] 
R1268Q* 
abolished  n.d.  abolished  rat  MDCK  Sf9  [105] 
abolished  n.d.  abolished  rat  ‐  MDCK  [108] 
abolished  n.d.  n.d.  rat  HEK293  ‐  [111] 
G238V  abolished 
rapid 
proteosomal 
degradation 
n.d.  rat  MDCK  Sf9  [105] 
impaired  rescued  n.d.  rat  HEK293  ‐  [111] 
R1057X  normal  n.d.  abolished  rat  ‐  MDCK  [108] 
A570T 
impaired  n.d.  normal  rat 
MDCK and 
HEK293  Sf9  [73] 
impaired  n.d.  reduced  rat  ‐  MDCK  [108] 
n.d.  n.d.  reduced  rat  ‐  MDCK‐rNTCP  [96 64] 
impaired  rescued  reduced  human  CHO‐K1  Hi5  [50] 
R432T  n.d.  n.d.  reduced  human     Sf9  [107] 
T1210P*  impaired  rescued  n.d.  rat  Can 10     [97, 103] 
R1128C*  impaired  rescued  n.d.  rat  Can 10  ‐  [97] 
abolished  rescued  n.d.  human  CHO‐K1  ‐  [50] 
R1050C 
impaired  n.d.  normal  rat  HEK293  Sf9  [73] 
impaired  n.d.  reduced  rat  MDCK  ‐  [108] 
impaired  rescued  n.d  human  CHO‐K1  ‐  [50] 
C336S  PFIC2***  normal  n.d.  normal  rat  MDCK  Sf9  [105] 
V444A 
risk for ICP 
normal  n.d.  normal  human  CHO‐K1  ‐  [50] 
I206V  normal  n.d.  reduced   human  HepG2  HeLa‐hNTCP  [51] 
Q558H  normal  n.d.  reduced   human  HepG2  HeLa‐hNTCP  [51] 
N591S  impaired  n.d.  normal  rat  HEK293  Sf9  [73] 
E1186K  impaired  n.d.  reduced   human  HepG2  HeLa‐hNTCP  [51] 
V444A 
risk for DILI  n.d.  n.d. 
reduced 
slightly  human  ‐  Sf9  [52] 
D676Y  n.d.  n.d.  reduced  human  ‐  Sf9  [52] 
G855R   n.d.  n.d.  reduced  human  ‐  Sf9  [52] 
